|
You received this email because your are a relation of SACEMA. To unsubscribe click
here. Having problems reading this email? Please click here to view online version |
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
We invite you to comment on our articles on the website If you have a suggestion for the editors or a comment on the accessibility and usefulness of the material in the Quarterly please mail us This online magazine is produced and developed by Red Earth Webdesign. |
Recently the Lancet published the results of a randomized controlled trial which failed to show the effectiveness of the vaginal microbidide gel Carraguard to protect women from becoming HIV infected. This article extensively describes the study methods and results. Furthermore, it reports on ongoing trials on microbicides similair to Carraguard, and those on microbicides that contain antiretroviral drugs (new generation).
A significant contributing factor to the high incidence rates of tuberculosis (TB) in countries such as South Africa is the phenomenon of reinfection leading to further disease episodes. Researchers of SACEMA explored the relationship between incidence of TB and reinfection further by constructing a model that simulates the epidemiology of a TB endemic. This article describes the results of this analysis and recommendations based on these.
The Lancet recently reported that universal HIV testing and immediate antiretroviral therapy (ART) for everyone diagnosed with HIV in countries such as South Africa could reduce new infections by 95% within ten years. This article describes the benefits and objections (costs, human resources, side effects, drug resistance) to the idea of starting all HIV positives on ART in South Africa, including the way forward.